molnupiravir in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Fischer (all doses), 2021 0.22 [0.01; 6.60]
MOVe-OUT, 2021 0.06 [0.00; 1.05]
0.10 [0.01 ; 0.92 ] Fischer (all doses), 2021, MOVe-OUT, 2021 2 0% 964 low not evaluable deathsdetailed results Fischer (all doses), 2021 0.22 [0.01; 6.60]
MOVe-OUT, 2021 0.06 [0.00; 1.05]
0.10 [0.01 ; 0.92 ] Fischer (all doses), 2021, MOVe-OUT, 2021 2 0% 964 low not evaluable hospitalization or deathdetailed results MOVe-OUT, 2021 0.48 [0.30; 0.78]
0.48 [0.30 ; 0.78 ] MOVe-OUT, 2021 1 0% 762 NA not evaluable hospitalizationdetailed results MOVe-OUT, 2021 0.49 [0.30; 0.79]
0.49 [0.30 ; 0.79 ] MOVe-OUT, 2021 1 0% 762 NA not evaluable viral clearance detailed results Fischer (all doses), 2021 14.50 [1.70; 123.69]
14.50 [1.70 ; 123.69 ] Fischer (all doses), 2021 1 0% 171 NA not evaluable viral clearance by day 7detailed results Fischer (all doses), 2021 14.50 [1.70; 123.69]
14.50 [1.70 ; 123.69 ] Fischer (all doses), 2021 1 0% 171 NA not evaluable AE leading to drug discontinuationdetailed results Fischer (all doses), 2021 0.88 [0.08; 9.94]
MOVe-OUT, 2021 0.49 [0.23; 1.05]
0.51 [0.25 ; 1.07 ] Fischer (all doses), 2021, MOVe-OUT, 2021 2 0% 1,613 low not evaluable serious adverse eventsdetailed results Fischer (all doses), 2021 1.34 [0.14; 13.10]
MOVe-OUT, 2021 0.70 [0.48; 1.03]
0.71 [0.49 ; 1.04 ] Fischer (all doses), 2021, MOVe-OUT, 2021 2 0% 1,613 low not evaluable adverse eventsdetailed results Fischer (all doses), 2021 1.05 [0.54; 2.02]
MOVe-OUT, 2021 0.89 [0.71; 1.11]
0.90 [0.73 ; 1.12 ] Fischer (all doses), 2021, MOVe-OUT, 2021 2 0% 1,613 low not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 16:02 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 97
- treatments: 941
- roots T: 290